Actelion is part of the Johnson & Johnson Family of Companies. We are leaders in the science and medicine of pulmonary arterial hypertension (PAH), with over 15 years of experience in this devastating cardiovascular disorder.
Find out more about our marketed products and our clinical development pipeline and how we developed Actelion into a leading company in the field of PAH.
Actelion is highly conscious of the fact that it’s people who make the difference. In turn, we have made sure our employees understand that we expect each of them to make a significant contribution.
Actelion’s products and late-stage development compounds target a number of different diseases.
Actelion considers sophisticated partnerships to strategically access technologies or products, and to maximize the value of our assets.
Actelion has operative affiliates in over 30 countries - explore our global operations.